Logo image of MBX

MBX BIOSCIENCES INC (MBX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MBX - US55287L1017 - Common Stock

29.86 USD
+1.43 (+5.03%)
Last: 12/12/2025, 8:00:00 PM
29.86 USD
0 (0%)
After Hours: 12/12/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, MBX scores 3 out of 10 in our fundamental rating. MBX was compared to 191 industry peers in the Pharmaceuticals industry. While MBX has a great health rating, there are worries on its profitability. MBX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MBX has reported negative net income.
In the past year MBX has reported a negative cash flow from operations.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of MBX (-20.12%) is comparable to the rest of the industry.
MBX has a Return On Equity of -20.77%. This is in the better half of the industry: MBX outperforms 67.02% of its industry peers.
Industry RankSector Rank
ROA -20.12%
ROE -20.77%
ROIC N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MBX has more shares outstanding
There is no outstanding debt for MBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 63.86 indicates that MBX is not in any danger for bankruptcy at the moment.
MBX has a better Altman-Z score (63.86) than 97.38% of its industry peers.
MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.86
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M

2.3 Liquidity

MBX has a Current Ratio of 32.95. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 32.95, MBX belongs to the best of the industry, outperforming 96.86% of the companies in the same industry.
A Quick Ratio of 32.95 indicates that MBX has no problem at all paying its short term obligations.
MBX has a Quick ratio of 32.95. This is amongst the best in the industry. MBX outperforms 96.86% of its industry peers.
Industry RankSector Rank
Current Ratio 32.95
Quick Ratio 32.95
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MBX have decreased strongly by -38.10% in the last year.
EPS 1Y (TTM)-38.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.58% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y77.18%
EPS Next 2Y31.68%
EPS Next 3Y18.56%
EPS Next 5Y11.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly Revenue VS EstimatesMBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

MBX's earnings are expected to grow with 18.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.68%
EPS Next 3Y18.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MBX BIOSCIENCES INC

NASDAQ:MBX (12/12/2025, 8:00:00 PM)

After market: 29.86 0 (0%)

29.86

+1.43 (+5.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-17 2026-03-17
Inst Owners80.04%
Inst Owner Change34.58%
Ins Owners3.1%
Ins Owner Change1.7%
Market Cap1.34B
Revenue(TTM)N/A
Net Income(TTM)-80.50M
Analysts86.67
Price Target59.8 (100.27%)
Short Float %14.02%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.26%
Min EPS beat(2)10.09%
Max EPS beat(2)24.42%
EPS beat(4)4
Avg EPS beat(4)15.51%
Min EPS beat(4)8.71%
Max EPS beat(4)24.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.64%
PT rev (3m)55.45%
EPS NQ rev (1m)4.31%
EPS NQ rev (3m)7.92%
EPS NY rev (1m)3.34%
EPS NY rev (3m)5.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 3.46
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS8.63
TBVpS8.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.12%
ROE -20.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 499.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.95
Quick Ratio 32.95
Altman-Z 63.86
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)409.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.34%
EPS Next Y77.18%
EPS Next 2Y31.68%
EPS Next 3Y18.56%
EPS Next 5Y11.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.71%
EBIT Next 3Y-33.03%
EBIT Next 5Y-15.18%
FCF growth 1Y-73.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71%
OCF growth 3YN/A
OCF growth 5YN/A

MBX BIOSCIENCES INC / MBX FAQ

What is the ChartMill fundamental rating of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBX.


Can you provide the valuation status for MBX BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to MBX BIOSCIENCES INC (MBX). This can be considered as Overvalued.


What is the profitability of MBX stock?

MBX BIOSCIENCES INC (MBX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MBX BIOSCIENCES INC?

The Earnings per Share (EPS) of MBX BIOSCIENCES INC (MBX) is expected to grow by 77.18% in the next year.